18 and older, any sex, with Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Objective Response RatePrimary· Responses measured by RECIST at 16 weeks from baseline
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Group
Value
95% CI
Checkpoint Blockade Immunotherapy Plus SBRT
11
Checkpoint Blockade Immunotherapy
6
Number of Participants With Adverse EventsSecondary· up to 5 years
Adverse events assessed from time of first dose to treatment completion (approximately 1 year)
Group
Value
95% CI
Checkpoint Blockade Immunotherapy Plus SBRT
58
Checkpoint Blockade Immunotherapy
48
Progression Free SurvivalSecondary· Assessed at 5 years
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Group
Value
95% CI
Checkpoint Blockade Immunotherapy Plus SBRT
2.38
1.95 – 3.37
Checkpoint Blockade Immunotherapy
1.88
1.82 – 2.81
Overall SurvivalSecondary· Assessed at 5 years
The time from starting treatment until death due to any cause.
Group
Value
95% CI
Checkpoint Blockade Immunotherapy Plus SBRT
14.1
8.46 – 25.2
Checkpoint Blockade Immunotherapy
12.6
7.14 – 29.2
Rate of Stable DiseaseSecondary· Assessed at 5 years
The rates of stable disease great than or equal to 6 months during and after SBRT in combination with CBI compared to CBI alone.
Group
Value
95% CI
Checkpoint Blockade Immunotherapy Plus SBRT
7
Checkpoint Blockade Immunotherapy
4
Adverse events — posted to ClinicalTrials.gov
Time frame: 5 years.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) combined with checkpoint blockaded immunotherapy (CBI) will improve the response to the anticancer treatment compared to CBI alone in patients with advanced metastatic cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Diego
Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02843165.